使用来迪派韦/索磷布韦治疗8周对丙型肝炎病毒再感染实现持续病毒学应答。
Treating Hepatitis C Virus Reinfection With 8 Weeks of Ledipasvir/Sofosbuvir Achieves Sustained Virologic Response.
作者信息
Rife Kelsey M, Lea Erin J, Hirsch Amy A, Falck-Ytter Yngve
机构信息
is a Hepatology Clinical Pharmacy Specialist, is an Infectious Diseases Clinical Pharmacist, is the Chief of the Gastroenterology and Hepatology Section, and is a Behavioral Health Psychologist, all at US Department of Veterans Affairs Northeast Ohio Healthcare System in Cleveland. Yngve Falck-Ytter is a Professor of Medicine, Erin Lea is an Adjunct Assistant Professor in the Department of Psychological Sciences, and Amy Hirsch is a Senior Clinical Instructor in the College of Medicine, all at Case Western Reserve University. Yngve Falck-Ytter is Faculty for the Gastroenterology Fellowship Program at University Hospitals.
出版信息
Fed Pract. 2021 Jun;38(6):282-285. doi: 10.12788/fp.0137.
Abstract
Three patients reinfected with hepatitis C virus after a sustained virologic response were considered treatment naïve and treated with a short-course direct acting antiviral regimen.
摘要
三名在获得持续病毒学应答后再次感染丙型肝炎病毒的患者被视为初治患者，并接受了短疗程直接抗病毒方案治疗。
相似文献
1
Treating Hepatitis C Virus Reinfection With 8 Weeks of Ledipasvir/Sofosbuvir Achieves Sustained Virologic Response.使用来迪派韦/索磷布韦治疗8周对丙型肝炎病毒再感染实现持续病毒学应答。
Fed Pract. 2021 Jun;38(6):282-285. doi: 10.12788/fp.0137.
2
The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection.来迪派韦索磷布韦治疗 12-17 岁 1 型丙型肝炎病毒感染青少年的安全性和有效性。
Hepatology. 2017 Aug;66(2):371-378. doi: 10.1002/hep.28995. Epub 2017 Jun 19.
3
Sustained Virologic Suppression After 4 Weeks of Ledipasvir/Sofosbuvir in Human Immunodeficiency Virus (HIV)/Hepatitis C Virus (HCV) Co-Infection.在 HIV/HCV 共感染患者中，使用雷迪帕韦/索磷布韦治疗 4 周后可实现持续病毒学抑制。
Am J Case Rep. 2020 Jun 4;21:e923326. doi: 10.12659/AJCR.923326.
4
Comparative treatment effectiveness of direct acting antiviral regimens for hepatitis C: Data from the Veterans administration.丙型肝炎直接抗病毒治疗方案的比较疗效：来自退伍军人管理局的数据。
J Gastroenterol Hepatol. 2017 Jun;32(6):1136-1142. doi: 10.1111/jgh.13652.
5
Ledipasvir-Sofosbuvir: A Once-Daily Oral Treatment Option for Chronic Hepatitis C Virus Genotype 1 Infection.来迪派韦-索磷布韦：慢性丙型肝炎病毒1型感染的每日一次口服治疗方案
Pharmacotherapy. 2016 May;36(5):562-74. doi: 10.1002/phar.1748. Epub 2016 May 12.
6
Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection.利巴韦林联合索磷布韦治疗 8 周或 12 周对 HCV 基因 2 型感染患者的疗效。
Gastroenterology. 2017 May;152(6):1366-1371. doi: 10.1053/j.gastro.2017.01.017. Epub 2017 Jan 27.
7
A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study.索磷布韦-雷迪帕韦治疗丙型肝炎病毒1b型肝硬化患者的不同视角：意大利丙型肝炎网络研究
J Viral Hepat. 2018 Jan;25(1):56-62. doi: 10.1111/jvh.12765. Epub 2017 Aug 30.
8
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.聚乙二醇干扰素α-2a 联合利巴韦林治疗慢性丙型肝炎
N Engl J Med. 2014 May 15;370(20):1879-88. doi: 10.1056/NEJMoa1402355. Epub 2014 Apr 10.
9
Tolerability and effectiveness of generic direct-acting antiviral drugs in eradication of hepatitis C genotype 4 among Egyptian patients.埃及患者中通用直接作用抗病毒药物对丙型肝炎基因型 4 的根除的耐受性和有效性。
Liver Int. 2019 May;39(5):835-843. doi: 10.1111/liv.14022. Epub 2019 Feb 6.
10
Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C.慢性丙型肝炎患者对 ledipasvir/sofosbuvir 治疗 8 周的应答存在亚组差异。
Open Forum Infect Dis. 2014 Dec 13;1(3):ofu110. doi: 10.1093/ofid/ofu110. eCollection 2014 Dec.
本文引用的文献
1
Staying hepatitis C negative: A systematic review and meta-analysis of cure and reinfection in people who inject drugs.保持丙型肝炎阴性：对注射吸毒者治愈和再感染的系统评价和荟萃分析。
Liver Int. 2019 Dec;39(12):2244-2260. doi: 10.1111/liv.14152. Epub 2019 Jun 10.
2
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.索磷布韦和维帕他韦治疗近期有注射吸毒史的丙型肝炎病毒感染（SIMPLIFY）：一项开放标签、单臂、4 期、多中心试验。
Lancet Gastroenterol Hepatol. 2018 Mar;3(3):153-161. doi: 10.1016/S2468-1253(17)30404-1. Epub 2018 Jan 6.
3
Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe.模型预测在欧洲，HCV 治疗对预防注射吸毒人群中 HCV 传播的影响。
J Hepatol. 2018 Mar;68(3):402-411. doi: 10.1016/j.jhep.2017.10.010. Epub 2018 Jan 8.
4
Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.针具交换计划和阿片类药物替代疗法预防注射吸毒者丙型肝炎传播
Cochrane Database Syst Rev. 2017 Sep 18;9(9):CD012021. doi: 10.1002/14651858.CD012021.pub2.
5
American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases.美国胃肠病学会协会弹性成像技术在慢性肝病中的作用技术评论。
Gastroenterology. 2017 May;152(6):1544-1577. doi: 10.1053/j.gastro.2017.03.016.
6
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.依巴司韦/格拉瑞韦治疗接受阿片类激动剂治疗的丙型肝炎病毒感染者：一项随机试验。
Ann Intern Med. 2016 Nov 1;165(9):625-634. doi: 10.7326/M16-0816. Epub 2016 Aug 9.
7
Hepatitis C reinfection after sustained virological response.丙型肝炎病毒持续应答后再感染。
J Hepatol. 2016 May;64(5):1020-1026. doi: 10.1016/j.jhep.2016.01.001. Epub 2016 Jan 11.
8
Recommendations for the management of hepatitis C virus infection among people who inject drugs.注射吸毒者丙型肝炎病毒感染管理建议
Int J Drug Policy. 2015 Oct;26(10):1028-38. doi: 10.1016/j.drugpo.2015.07.005. Epub 2015 Jul 17.
9
Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C.慢性丙型肝炎治疗后获得持续病毒学应答的囚犯中丙型肝炎病毒再感染。
J Hepatol. 2013 Jul;59(1):45-51. doi: 10.1016/j.jhep.2013.03.008. Epub 2013 Mar 22.
10
Low incidence of reinfection with the hepatitis C virus following treatment in active drug users in Amsterdam.在阿姆斯特丹的活跃药物使用者中，治疗后丙型肝炎病毒再感染的发生率较低。
Eur J Gastroenterol Hepatol. 2012 Nov;24(11):1302-7. doi: 10.1097/MEG.0b013e32835702a8.
Zotero 插件